The Stop TB Partnership and the Communities Living with HIV, Tuberculosis and affected by Malaria Delegation of the Global Fund has agreed to strengthen partnership, collaboration and networking.

ECDC and the European Respiratory Society (ERS) have developed 21 patient-centred standards that aim to guide clinicians and public health workers in their daily work to ensure optimal diagnosis, treatment and prevention of tuberculosis (TB) in Europe.

The latest World Health Organization / European Union plans to counter the trade in counterfeit and substandard medicines aim to ensure that medicines in the developing world are safe. As such, though both plans appropriately address quality issues, they fall short of adequate coordination and collaboration with each other, and also present substantial flaws.

The need to ensure that people in Africa have access to essential, high quality, safe  and affordable medicines has just received a major boost with the launch of the East African Community (EAC) Medicines Registration Harmonization Project in Arusha, Tanzania, on 30 March 2011. 

South African researchers said on Friday they were conducting medical trials to shorten the duration of tuberculosis treatment, to make it easier for patients to complete the full regimen.

30 March 2012 - The Working Group on New Drugs invites people around the world to submit videos, photos or written accounts of new approaches that can help to achieve zero deaths from TB in this generation.

Only 50% of countries in receipt of grants from the Global Fund to Fight AIDS, Tuberculosis and Malaria provide tuberculosis (TB) services in prisons, according to research published in a special supplement of the Journal of Infectious Diseases.

Supreme Court of Appeal overturns Cape High Court's TB in prisons ruling.

"Losing Ground" describes the impact of funding shortfalls in critical areas of HIV and TB in 13 countries where MSF work.

SAN DIEGO, March 26, 2012 — A two-drug combination is one of the most promising advances in decades for the treatment of tuberculosis (TB) — a disease that kills 2 million people annually — a scientist reported today at the 243 National Meeting & Exposition of the American Chemical Society (ACS). The treatment, which combines two medications already approved by the U.S. Food and Drug Administration (FDA), delivers a knockout punch to forms of TB that shrug off other antibiotics.